ARTICLE

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

Nina Hanke¹, Sebastian Frechen², Daniel Moj¹, Hannah Britz¹, Thomas Eissing², Thomas Wendl² and Thorsten Lehr¹,*

According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug–drug interactions (DDIs) and may offer an alternative to dedicated clinical trials. This study provides whole-body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology (OSP) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical DDI studies. In total, 112 studies were used for model development and 57 studies for DDI prediction. 93% of the predicted area under the plasma concentration-time curve (AUC) ratios and 94% of the peak plasma concentration (C_{\text{max}}) ratios are within twofold of the observed values. This study lays a cornerstone for the qualification of the OSP platform with regard to reliable PBPK predictions of enzyme-mediated and transporter-mediated DDIs during model-informed drug development. All presented models are provided open-source and transparently documented.

CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 647–659; doi:10.1002/psp4.12343; published online on 07 September 2018.

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
PBPK modeling is increasingly used for DDI analysis. To investigate and predict the DDI potential of new drugs with the help of PBPK, models of index perpetrator and victim drugs are needed.

WHAT QUESTION DID THIS STUDY ADDRESS?
The aim of this study was to provide whole-body PBPK models of important CYP3A4 and P-gp perpetrator and victim drugs that are all compatible, evaluated, and fit for use in PBPK DDI modeling.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study adds transparently built and evaluated PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin, integrating the current knowledge on the relevant pharmacokinetic mechanisms of these six drugs with insights gained during model development.

HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?
A publicly available library, providing comprehensive PBPK models of the recommended DDI inhibitors, inducers, and substrates, evaluated and ready to use for their application in DDI modeling, has the potential to foster open collaboration and to accelerate the drug development process.

Physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict the pharmacokinetic (PK) of drugs and the magnitude of drug–drug interactions (DDIs). It is applied at increasingly early stages during drug development and is recommended by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the design of clinical DDI trials and population PK studies. Furthermore, PBPK may even offer an alternative to dedicated clinical trials, to find dosing recommendations for the co-administration of interacting substances, or the treatment of special populations.¹ ²

To investigate and predict the DDI potential of new drugs with the help of PBPK, models of index perpetrator and victim drugs are needed. A library of PBPK models of recommended DDI inhibitors, inducers, and substrates, evaluated for their application in DDI modeling, has the potential to accelerate the drug development process.

The aim of the presented work was to develop and carefully evaluate whole-body PBPK models of frequently used
perpetrator and victim drugs and to provide them to the PBPK modeling community. Focusing on cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) as major interaction pathways affecting approximately half of all drugs in use, models of rifampicin (most prominent CYP3A4 and P-gp inducer), itraconazole (competitive CYP3A4 and P-gp inhibitor), clarithromycin (mechanism-based CYP3A4 inactivator and competitive P-gp inhibitor), midazolam, alfentanil (specific CYP3A4 substrates), and digoxin (specific P-gp substrate) have been established. All selected compounds are recommended by the FDA for application in clinical DDI trials.

The perpetrator and victim drug models were developed independently of each other, without the use of data from clinical DDI studies for parameter optimization. With this approach, the prediction of co-administration studies could be utilized as an additional means of model evaluation. Being recommended by the FDA for DDI potential assessment, the six selected compounds have been co-administered in different combinations in many clinical trials, providing ample data for the evaluation of DDI predictions. Figure 1 shows the developed DDI modeling network of interacting perpetrator and victim drugs, assessing multiple combinations for mutual DDI evaluation.

Clinical DDI studies, for example, the full inhibition of an important metabolizing enzyme, provide valuable information on the fraction of victim drug that is normally eliminated via this pathway (“fraction metabolized”). Therefore, victim drug plasma concentrations during co-administration of perpetrators can serve as additional information for victim drug model evaluation. Furthermore, correct prediction of the impact of a perpetrator drug on the PK of a victim drug indicates that the model is able to describe the perpetrator concentrations at the sites of inhibition or induction. This is not trivial, as drug concentrations are generally measured in blood plasma, but the interactions take place in other compartments, such as the intracellular space of the liver or intestine. Taken together, DDI studies provide additional information on both, the perpetrator and the victim drug PKs, and their correct prediction is a challenge for both models and a valid means of model evaluation.

The aim of this study was to establish and thoroughly evaluate PBPK models of relevant DDI perpetrator and victim drugs. The presented models are whole-body PBPK models, allowing for dynamic DDI assessment in all organs expressing the affected enzyme or transporter. Evaluations indicate that the models are fit for DDI prediction. The model files have been made publicly available as supplementary material to this paper (Data S1-S6) and in the Open Systems Pharmacology (OSP) repository (www.open-systems-pharmacology.org), as tools for the drug development and clinical research community to assess the DDI potential of investigational drugs, to inform the design of clinical trials or to be expanded for predictions in special populations.
METHODS
Software
PBPK modeling was performed with PK-Sim and MoBi modeling software version 7.1.0 (part of the OSP Suite). The OSP Suite makes formerly commercial software tools PK-Sim and MoBi available as freeware under the GPLv2 License. The software allows the modification of system parameters and the model structure by the (qualified) user and the source code is publicly available on GitHub (accessible via www.open-systems-pharmacology.org), together with published models and tutorials. Details on how to modify a PBPK model in PK-Sim can be found, for example, in Kuepfer et al., the PK-Sim/MoBi user manual, and in the user forum. Parameter optimization was accomplished using the Monte Carlo algorithm of the “Parameter Identification Toolbox” in MATLAB version R2013b (The MathWorks, Natick, MA) or in PK-Sim. Sensitivity analyses were performed within PK-Sim. Plots and PK parameter analyses were compiled with MATLAB.

Model development
Models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin were built combining bottom-up and top-down techniques. To establish the models, an extensive literature search was conducted, collecting (i) physicochemical parameters, (ii) information on absorption, distribution, metabolism, and excretion processes, and (iii) clinical studies of intravenous and oral administration to healthy subjects in single-dosing and multiple-dosing regimens, covering the full dosing range published. All data used in this analysis has been taken from previously published human or preclinical studies.

The PBPK models were developed based on a healthy male European individual, 30 years of age, with a body weight of 73 kg, and a height of 176 cm. Physiological parameters, like organ volumes, blood flow rates, and surface permeabilities, are provided within the software. Absorption, distribution, metabolism, and excretion-relevant proteins reported to govern the PK of a drug, such as metabolizing enzymes, transporters, or binding partners, were implemented into the models and tested. Whenever available and in accordance with literature protein expression, the PK-Sim expression database reverse transcription-polymerase chain reaction (RT-PCR) profiles were used to define the relative tissue distribution of these proteins. For parameters that could not be informed from (in vitro) experimental data, parameter identification based on plasma concentration-time profiles was performed using a subset of the available clinical studies (training dataset) for optimization. The decision of which studies to include into the training dataset was based on the number of studies available and the information contained in the different studies (dosing regimen, study size, sampling times, fraction excreted measurements, etc.).

Model selection was based on the ability of the model to describe (training dataset) and predict (test dataset) plasma concentration-time profiles from all published clinical studies as well as fraction excreted unchanged to urine. Furthermore, physiological plausibility, precision and covariance of parameter estimates, and population predictions were assessed.

Model evaluation
The models were evaluated by comparison of concentration-time profiles, area under the plasma concentration-time curve (AUC), and peak plasma concentration ($C_{\text{max}}$) values resulting from our simulations to the values observed during clinical studies. As a quantitative measure of the descriptive and predictive performance of each model, the geometric mean fold error was calculated according to Eq. 1:

$$GMFE = 10^{\frac{1}{n} \sum \log_{10} \left( \frac{\text{pred PK parameter}}{\text{obs PK parameter}} \right)}$$

with $GMFE = \text{geometric mean fold error of all AUC or } C_{\text{max}}$, predictions of the respective model, $\text{pred PK parameter} = \text{predicted AUC or } C_{\text{max}}$, $\text{obs PK parameter} = \text{observed AUC or } C_{\text{max}}$, and $n = \text{number of studies}$. Furthermore, models were evaluated by their ability to adequately predict the clinical data of all DDI studies available from literature. For this additional evaluation, the final perpetrator models were coupled to victim drug models using measured values (from literature) to inform the different interaction processes without further adjustment. Successful prediction of the victim drug plasma concentration-time profiles during co-administration is interpreted as indication of the correct simulation of the perpetrator drug concentration at the site where the DDI takes effect as well as of the appropriate implementation of the victim drugs’ affected disposition pathways.

DDI network development
Mathematical implementation of the induction and inhibition processes in general is specified in Section 1 of Appendix S1. The final rifampicin model was coupled to models of midazolam, alfentanil, itraconazole, and digoxin, to assess its DDI performance with CYP3A4 and P-gp substrates. To describe the influence of rifampicin on these victim drugs, induction and simultaneous competitive inhibition of CYP3A4 and P-gp by rifampicin have been added. Furthermore, inhibition of midazolam and digoxin elimination by itraconazole and by clarithromycin were modeled and compared to observed clinical data, evaluating the performance of these two victim drug models with two different CYP3A4 and P-gp inhibitors. Inhibition of alfentanil metabolism by itraconazole or clarithromycin was not tested, as there are no clinical studies available to compare to.

All induction and inhibition processes were modeled using interaction parameter values either identified during the development of the perpetrator models if no experimental values could be found to parameterize their auto-induction or auto-inhibition (using multiple-dose perpetrator studies only, without co-administration of victim drugs), or taken from literature without further adjustment or fitting, as a means of further evaluation of the perpetrator and victim drug models.

DDI network evaluation
The DDI modeling performance was assessed by comparison of predicted vs. observed victim drug plasma concentration-time profiles during co-administration, DDI AUC ratios (Eq. 2), and DDI $C_{\text{max}}$ ratios (Eq. 3):

$$\text{DDI AUC ratio} = \frac{\text{AUC}_{\text{victim drug during co-administration}}}{\text{AUC}_{\text{victim drug}}}$$

$$\text{DDI } C_{\text{max}} \text{ ratio} = \frac{\text{C}_{\text{max, victim drug during co-administration}}}{\text{C}_{\text{max, victim drug}}}$$
As a quantitative measure of the prediction accuracy of each DDI interaction, GMFEs of the predicted DDI AUC ratios and DDI $C_{\text{max}}$ ratios were calculated according to Eq. 1.

**Sensitivity analysis**

Sensitivity of the final models to single parameters (local sensitivity analysis) was calculated, measured as changes of the AUC extrapolated to infinity (for single-dose administration drugs) or of the AUC of one dosing interval in steady-state conditions (for multiple-dose administration drugs) of a simulation with administration of the highest common dose. Parameters were included into the analysis if they have been optimized, if they might have a strong influence due to calculation methods used in the model (e.g., lipophilicity and fraction unbound), if they are related to optimized parameters, or if they had significant impact in other models (e.g., solubility and blood/plasma concentration ratio). Sensitivity to a parameter is calculated as the ratio of the relative change of the simulated AUC to the relative variation of the parameter around the value used in the final model (Eq. 4):

$$S = \frac{\Delta \text{AUC}}{\text{AUC}} \cdot \frac{p}{\Delta p},$$

with $S$ = sensitivity of the AUC to the examined model parameter, $\Delta \text{AUC} =$ change of the AUC, $\text{AUC} =$ simulated AUC with the original parameter value, $\Delta p =$ change of the examined model parameter value, and $p =$ original model parameter value. A sensitivity value of +1.0 signifies that a 10% increase of the examined parameter causes a 10% increase of the simulated AUC.

**Virtual population characteristics**

To quantitatively predict the variability of the simulated plasma concentration-time profiles, virtual populations of 100 individuals within an age range of 20–50 years were generated. Weight, height, and many physiological parameters, such as organ volumes, blood flow rates, and gastrointestinal characteristics, were varied according to published data as implemented into the software. In addition to the variability in drug PK that results from these physiological differences within the virtual populations, the expression levels of the implemented drug metabolizing enzymes, transporters, and protein binding partners were varied around their reference values. If available, default population variabilities for enzyme expression in PK-Sim were used. Otherwise, log-normal distribution of the protein expression level in the population was assumed and variabilities were implemented as geometric SDs derived from literature reports. If no valid source could be found, log-normal distributions with a moderate geometric SD of 1.4 (~35% coefficient of variation) were assumed. Please refer to Table S7 in Appendix S1 for an overview.

Population simulations were generated and compared with observed data. Observed data were most often reported in terms of arithmetic means and SDs. To allow comparison of observed and simulated means, simulated 68% population prediction intervals were plotted that correspond to the range span of ±1 SD around the mean assuming normal distribution.

**RESULTS**

**Model development and evaluation**

Of the total of 112 studies, in detail 16 studies of rifampicin, 27 studies of itraconazole, 17 studies of clarithromycin, 7 studies of midazolam, 7 studies of alfentanil, and 38 studies of digoxin administration, were used for model development. The respective modeling results are presented in Section 2 of Appendix S1. This includes tables listing the clinical studies used for model development and evaluation, with administration protocols and study population details (Tables S1a, S2a, S3a, S4a, S5a, S6a in Appendix S1), descriptions of the final models, and tables listing the respective drug-dependent parameters (Tables S1b, S2b, S3b, S4b, S5b, S6b in Appendix S1).

All models show accurate and precise descriptive and predictive performance for intravenous and oral administration. Plots of population predicted compared with observed plasma concentration-time profiles of all studies obtained from literature are shown as semilogarithmic (Figures S1c, S2c, S3c, S4c, S5c, S6c in Appendix S1) as well as linear plots (Figures S1d, S2d, S3d, S4d, S5d, S6d in Appendix S1). In addition, predicted compared to observed AUC and $C_{\text{max}}$ values with calculated GMFEs (also listed in Tables S1a, S2a, S3a, S4a, S5a, S6a in Appendix S1) and sensitivity analysis results (Figures S1e, S2e, S3e, S4e, S5e, S6e in Appendix S1) are presented. System-dependent parameters are given in Table S7 in Appendix S1.

**DDI network modeling**

Of the total of 57 studies, in detail 18 clinical studies of rifampicin with midazolam, 12 studies of rifampicin with alfentanil, 1 study of rifampicin with itraconazole, 10 studies of itraconazole with midazolam, 4 studies of clarithromycin with midazolam, 7 studies of rifampicin with digoxin, 1 study of itraconazole with digoxin, and 4 studies of the interaction of clarithromycin with digoxin were predicted and compared with observed data. Table 1 lists all modeled clinical DDI studies, with administration protocols and study population details. The parameters to model the CYP3A4 and P-gp induction and inhibition processes are described in Section 3 of Appendix S1.

**Figure 2** presents a selection of the different modeled CYP3A4 DDIs, showing population predicted compared with observed victim drug plasma concentration-time profiles of one study each of the rifampicin-midazolam, rifampicin-alfentanil, itraconazole-midazolam, and clarithromycin-midazolam DDIs, selected for their clinically relevant doses of perpetrator and victim drug. **Figure 3** presents a selection of the different modeled P-gp DDIs, showing population predicted compared with observed victim drug plasma concentration-time profiles of one study each of the rifampicin-digoxin, itraconazole-digoxin, and clarithromycin-digoxin DDIs, selected for their clinically relevant doses of perpetrator and victim drug. Please refer to
| Perpetrator (mg) | Victim (mg) | Dose gap (hours) | n | Males (%) | Permitted/observed AUC ratio | Predicted AUC ratio | Predicted C<sub>max</sub> ratio | GMFE (range) | Pred within twofold | Reference |
|----------------|-------------|-----------------|---|-----------|-----------------------------|-------------------|-------------------|-------------|-------------------|-----------|
| Rifampicin     | Midazolam   |                 |    |           |                             |                   |                   |             |                   |           |
| 600, q.d.      | 1.0, i.v. (bol) | 24 | 9  | 100      | 0.460                      | 0.378             | 1.22              |             |                   | Kharasch 1997 |
| 600, q.d.      | 1.0, i.v. (bol) | 8  | 10 | 50       | 0.470                      | 0.521             | 0.90              |             |                   | Kharasch 2004 |
| 600, q.d.      | 1.0, i.v. (bol) | 8  | 6  | 50       | 0.470                      | 0.481             | 0.98              |             |                   | Kharasch 2004 |
| 600, q.d.      | 2.0, i.v. (-) | 24 | 8  | 100      | 0.460                      | 0.655             | 0.70              |             |                   | Link 2008   |
| 600, q.d.      | 0.05/kg, i.v. (bol) | 12 | 3a | 100      | 0.480                      | 0.579             | 0.83              |             |                   | Szalat 2007  |
| 600, q.d.      | 0.05/kg, i.v. (bol) | 12 | 14 | 100      | 0.510                      | 0.512             | 1.00              |             |                   | Gorski 2003  |
| 600, q.d.      | 2.0, p.o. (syr) | 0  | 11 | 100      | 0.220                      | 0.123             | 1.78              | 0.300       | 0.162            | 1.85 Reitman 2011 |
| 600, q.d.      | 2.0, p.o. (syr) | 168 | 11 | 100      | 0.370                      | 0.383             | 0.97              | 0.470       | 0.403            | 1.17 Reitman 2011 |
| 600, q.d.      | 2.0, p.o. (syr) | 336 | 11 | 100      | 0.910                      | 0.815             | 1.12              | 0.940       | 0.731            | 1.29 Reitman 2011 |
| 600, q.d.      | 3.0, p.o. (syr) | 8  | 10 | 50       | 0.040                      | 0.053             | 0.76              | 0.070       | 0.110            | 0.64 Kharasch 2004 |
| 600, q.d.      | 4.0, control/6.0 | 12 | 14 | 100      | 0.040                      | 0.032             | 1.25              | 0.070       | 0.051            | 1.37 Gorski 2003 |
| 600, q.d.      | 0.075/kg, p.o. (syr) | 22 | 18 | 50       | 0.040                      | 0.124             | 0.32              | 0.060       | 0.170            | 0.35 Chung 2006 |
| 450, q.d.      | 7.5, p.o. (sol) | 17 | 4  | 38       | 0.040                      | 0.052             | 0.77              | 0.070       | 0.112            | 0.63 Eap 2004 |
| 600, q.d.      | 7.5, p.o. (-) | 24 | 8  | 100      | 0.040                      | 0.016             | 2.57              | 0.060       | 0.035            | 1.72 Link 2008 |
| 300, b.i.d.    | 8.0, p.o. (-) | 27 | 19 | 53       | 0.060                      | 0.057             | 1.05              | 0.100       | 0.121            | 0.83 Gurley 2006 |
| 300, b.i.d.    | 8.0, p.o. (-) | 2  | 16 | 50       | 0.060                      | 0.060             | 0.99              | 0.100       | 0.108            | 0.93 Gurley 2008 |
| 600, q.d.      | 15.0, p.o. (tab) | 17 | 10 | 50       | 0.050                      | 0.041             | 1.21              | 0.050       | 0.064            | 0.79 Backman 1996 |
| 600, q.d.      | 15.0, p.o. (tab) | 17 | 9  | 44       | 0.100                      | 0.098             | 1.02              | 0.130       | 0.193            | 0.67 Backman 1998 |

GMFE (range): 1.30 (1.00–3.11) 1.48 (1.08–2.83)
Pred within twofold: 16/18 11/12

Rifampicin Alfentanil

5.0, q.d. | 0.015/kg, i.v. (-) | 10 | 12 | 67 | 0.750 | 0.791 | 0.95 | – | – | – | Kharasch 2011 |
10.0, q.d. | 0.015/kg, i.v. (-) | 10 | 12 | 67 | 0.660 | 0.712 | 0.93 | – | – | – | Kharasch 2011 |
25.0, q.d. | 0.015/kg, i.v. (-) | 10 | 12 | 67 | 0.560 | 0.564 | 0.99 | – | – | – | Kharasch 2011 |
75.0, q.d. | 0.015/kg, i.v. (-) | 10 | 12 | 67 | 0.480 | 0.474 | 1.01 | – | – | – | Kharasch 2011 |
600, q.d. | 0.015/kg, i.v. (bol) | 10 | 10 | 50 | 0.428 | 0.375 | 1.14 | – | – | – | Kharasch 2004 |
600, q.d. | 0.015/kg, i.v. (bol) | 12 | 6  | 50 | 0.426 | 0.433 | 0.98 | – | – | – | Phimmasone 2001 |
600, q.d. | 0.02/kg, i.v. (bol) | 24 | 9  | 100 | 0.425 | 0.362 | 1.17 | – | – | – | Kharasch 1997 |
600, q.d. | 0.06/kg, p.o. (sol) | 10 | 10 | 50 | 0.084 | 0.046 | 1.84 | 0.139 | 0.111 | 1.25 | Kharasch 2004 |
5.0, q.d. | 0.075/kg, p.o. (sol) | 10 | 12 | 67 | 0.519 | 0.692 | 0.75 | 0.606 | 0.863 | 0.70 | Kharasch 2011 |
10.0, q.d. | 0.075/kg, p.o. (sol) | 10 | 12 | 67 | 0.399 | 0.555 | 0.72 | 0.498 | 0.863 | 0.58 | Kharasch 2011 |
25.0, q.d. | 0.075/kg, p.o. (sol) | 10 | 12 | 67 | 0.270 | 0.295 | 0.92 | 0.365 | 0.490 | 0.75 | Kharasch 2011 |

(continues)
Table 1 (Continued)

| Perpetrator (mg) | Victim (mg) | Dose gap (hours) | n | Males (%) | Predicted AUC<sub>ratio</sub> | Observed AUC<sub>ratio</sub> | Pred/Obs AUC<sub>ratio</sub> | Predicted C<sub>max</sub> ratio | Observed C<sub>max</sub> ratio | Pred/Obs C<sub>max</sub> ratio | Reference |
|-----------------|-------------|------------------|---|-----------|-----------------------------|-----------------------------|-----------------------------|-------------------------------|-----------------------------|-------------------------------|-----------|
| 75.0, q.d.      | 0.075/kg, p.o. (sol) | 10 | 12 | 67 | 0.170 | 0.123 | 1.38 | 0.246 | 0.255 | 0.96 | Kharasch 2011²⁶ |
| Rifampicin      | Itraconazole | 600, q.d. | 200, b.i.d. (cap), fed | 12 | 2b | 100 | 0.015 | 0.018 | 0.83 | – | – | – | Tucker 1992³⁷ |
| Itraconazole    | Midazolam   | 200, q.d. (cap), fast | 75.0, p.o. (bol) | 2 | 12 | 58 | 2.360 | 3.220 | 0.73 | – | – | – | Olkkola 1996³⁸ |
| Clarithromycin  | Midazolam   | 500, b.i.d. | 0.05/kg, i.v. (bol) | 2 | 16 | 50 | 3.252 | 2.748 | 1.18 | – | – | – | Gorski 1998⁴² |
| Rifampicin      | Digoxin     | 600, q.d. | 1.0, i.v. (0.5 hours) | 8⁶ | 8 | 100 | 0.780 | 0.905 | 0.86 | – | – | – | Greiner 1999⁴⁶ |

GMFE (range) 1.19 (1.01–1.84) 1.34 (1.04–1.73)
Pred within twofold 12/12 5/5

GMFE (range) 1.20
Pred within twofold 1/1

GMFE (range) 1.55 (1.04–2.35) 1.33 (1.02–1.78)
Pred within twofold 9/10 6/6

GMFE (range) 1.25 (1.08–1.53) 1.29 (1.13–1.48)
Pred within twofold 4/4 2/2

GMFE (range) 1.41 (1.05–2.36) 1.36 (1.00–2.36)
Pred within twofold 6/7 4/5

(continues)
| Perpetrator (mg)       | Victim (mg)       | Dose gap (hours) | n   | Males (%) | Predicted AUC<sub>ratio</sub> | Observed AUC<sub>ratio</sub> | Pred/Obs AUC<sub>ratio</sub> | Predicted C<sub>max ratio</sub> | Observed C<sub>max ratio</sub> | Pred/Obs C<sub>max ratio</sub> | Reference                      |
|-----------------------|------------------|------------------|-----|-----------|-------------------------------|-----------------------------|-----------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------------|
| **Itraconazole**       | **Digoxin**      |                  |     |           |                               |                             |                             |                               |                               |                               |                                 |
| 200, q.d. (cap), fast  | 0.5, p.o. (tab)  | 1                | 10  | 10        | 1.399                         | 1.610                       | 0.87                        | 1.465                         | 1.340                         | 1.09                          | Jalava 1997<sup>48</sup>        |
|                       |                  |                  |     |           | GMFE                          |                             |                             |                               |                               |                               |                                 |
|                       |                  |                  |     |           |                               |                             |                             | Pred within twofold           | 1/1                           |                               |                                 |
| **Clarithromycin**     | **Digoxin**      |                  |     |           |                               |                             |                             |                               |                               |                               |                                 |
| 200, b.i.d.            | 0.5, i.v. (1 hours) | 0               | 9   | 100       | 1.020                         | 0.980                       | 1.04                        | 1.060                         | 1.185                         | 1.04                          | Tsutsumi 2002<sup>49</sup>      |
| 250, b.i.d.            | 0.01/kg, i.v. (bol) | 2               | 3   | 100       | 1.060                         | 1.185                       | 0.89                        | 1.350                         | 1.750                         | 0.89                          | Rengelshausen 2003<sup>50</sup> |
| 500, b.i.d.            | 0.25, p.o. (--)  | 0                | 18  | 50        | 1.310                         | 1.466                       | 0.89                        | 1.350                         | 1.750                         | 0.89                          | Rengelshausen 2003<sup>50</sup> |
| 250, b.i.d.            | 0.75, p.o. (tab) | 0.5              | 12  | 100       | 1.240                         | 1.643                       | 0.75                        | 1.420                         | 1.833                         | 0.77                          | Gurley 2008b<sup>46</sup>       |
|                       |                  |                  |     |           | GMFE (range)                  | 1.15 (1.04–1.32)            |                             |                               |                               |                               |                                 |
|                       |                  |                  |     |           | Pred within twofold           | 4/4                         |                             |                               |                               |                               |                                 |

AUC, area under the plasma concentration–time curve; bol, bolus; cap, capsule; C<sub>max</sub>, peak plasma concentration; DDI, drug–drug interaction; fast, oral administration in fasted conditions; fed, oral administration with a meal; GMFE, geometric mean fold error; obs, observed; pred, predicted; sol, solution; syr, syrup; tab, tablet.

<sup>a</sup>Cerebrotendinous xanthomatosis (CTX) patients,
<sup>b</sup>coccidioidomycosis patients,
<sup>c</sup>see Reitman et al.<sup>12</sup>,
<sup>d</sup>personal communication, Rifampicin-Midazolam: 0–∞ AUC<sub>ratio</sub>, Rifampicin-Aflentanil: 0–∞ AUC<sub>ratio</sub>, Rifampicin-Digoxin: 3 hours AUC<sub>ratio</sub>, Rifampicin-Itraconazole: 12 hours AUC<sub>ratio</sub>, Itraconazole-Midazolam: 0–∞ AUC<sub>ratio</sub>, Itraconazole-Digoxin: 12 hours AUC<sub>ratio</sub>, Clarithromycin-Midazolam: 0–∞ or 2–4 hours AUC<sub>ratio</sub>, Clarithromycin-Digoxin: 0–∞ or 24 hours AUC<sub>ratio</sub>, matching reported observed values, –, not given.
Section 3 of Appendix S1 for the results of all 57 DDI studies, shown in Figures S8a, S9a, S11a, S12a, S13a, S14a, S15a in Appendix S1 (semilogarithmic), Figures S8b, S9b, S11b, S12b, S13b, S14b, S15b in Appendix S1 (linear), and Table S10 in Appendix S1, demonstrating the good predictive performance for all modeled DDIs.

Modeled induction and de-induction of CYP3A4 enzyme activity in the liver and duodenum is presented in Figure 4. The combination of simulated intracellular rifampicin concentrations and chosen induction parameters (half-maximal effective concentration (EC$_{50}$) = 0.34 μmol/l, maximum effect (Emax) = 9) leads to CYP3A4 activity increases of 7.8-fold in the liver and of 6.7-fold in the duodenum with a 600 mg q.d. rifampicin regimen (Figure 4a). De-induction depends on the half-lives of the perpetrator and the induced protein; we implemented CYP3A4 with protein half-lives of 36 and 23 hours in the liver and intestine, respectively$^{10,11}$ (see Table S7 in Appendix S1). De-induction kinetics were evaluated by prediction of midazolam PK when administered 1, 2, or 4 weeks after the last dose of rifampicin, as studied by Reitman et al.$^{12}$ The rifampicin-midazolam model successfully predicts the time course of CYP3A4 activity return to baseline after the last dose of rifampicin, shown by the correct simulation of the midazolam plasma concentration-time profiles of this study (Figure 4b).
All victim drug plasma concentration-time profiles before and during co-administration with the different perpetrators are well predicted over the full range of administered doses and administration protocols. Predicted compared with observed DDI AUC ratios and $C_{\text{max}}$ ratios with calculated GMFEs for each perpetrator-victim pair are summarized in Table 1. Correlation of predicted to observed DDI AUC ratios and $C_{\text{max}}$ ratios of all 57 modeled interaction studies, illustrating the performance of the entire DDI network, is presented in Figure 5.

**DISCUSSION**

Comprehensive whole-body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin have been successfully developed, incorporating all current knowledge on the processes controlling the PKs of these drugs. All models were established using a large number of clinical studies and all models show a good performance over the full range of administered doses and administration protocols. Model evaluation comprised comparison of predicted with observed concentration-time profiles, AUC, and $C_{\text{max}}$ values, calculation of GMFEs as a measure of descriptive and predictive performance, and application of the independently developed models for DDI prediction.

Sensitivity analyses demonstrate that all models are sensitive to lipophilicity, fraction unbound, and the catalytic rate constants of influential eliminating enzymes or transporters. This result is expected, as the lipophilicity values are used for calculation of membrane permeabilities and partition coefficients, fraction unbound in plasma directly controls the concentration of drug available for passive distribution, transport, and metabolization from the blood, and the catalytic rate constants of the major eliminating enzymes or transporters naturally have a large impact on the predicted clearance and AUC. Experimental values were used for parameterization wherever possible. For example, fraction unbound was fixed to reported experimental values in five of the six models. For itraconazole, the attempts to set fraction...
Figure 4 Cytochrome P450 (CYP3A4) induction and de-induction. (a) Fold change of predicted CYP3A4 concentrations in liver (solid blue line) and duodenum (dashed red line) before, during, and after a 600 mg q.d. rifampicin regimen. Shown are population prediction arithmetic means (lines) and 68% population prediction intervals (shaded areas). (b) Population simulation arithmetic means (lines) and observed (squares, triangles, and dots) midazolam plasma concentration-time profiles during simultaneous administration of midazolam and rifampicin (red line and squares) or administration of midazolam 7 days (light blue line and triangles), 14 days (blue line and triangles) or 28 days (dark blue line and dots) after the last dose of a 600 mg q.d. rifampicin treatment. Observed data are from Reitman et al. Predicted and observed DDI area under the plasma concentration-time curve ratios and DDI peak plasma concentration ratios are given in Table 1.

Figure 5 Correlation of predicted to observed DDI area under the plasma concentration-time curve (AUC) ratios and DDI peak plasma concentration ($C_{\text{max}}$) ratios. The upper panel illustrates the cytochrome P450 (CYP3A4) DDI prediction performance, the lower panel illustrates the P-glycoprotein (P-gp) DDI prediction performance of the network. (a, d) DDI AUC ratios of intravenously administered victim drugs, (b, e) DDI AUC ratios of orally administered victim drugs, and (c, f) DDI $C_{\text{max}}$ ratios of orally administered victim drugs. The line of identity and the prediction acceptance limits proposed by Guest et al. are shown as solid lines. The 0.5-fold to 2.0-fold acceptance limits are shown as dashed lines. Induction of elimination pathways by rifampicin results in DDI ratios <1, inhibition of elimination pathways by itraconazole or clarithromycin results in DDI ratios >1. Study references and values of predicted and observed DDI AUC ratios and DDI $C_{\text{max}}$ ratios are listed in Table 1.
unbound in plasma to one of the widely differing literature values (0.2–3.6%) did not result in a satisfactory model and, therefore, fraction unbound was optimized within the literature range (0.6%).

The presented rifampicin model accounts for metabolism by the arylacetamide deacetylase (AADAC), and transport by organic anion-transporting polypeptide (OATP)1B1 and P-gp, as described in the literature. Metabolism by CYP3A4 has not been implemented, as currently there is no conclusive evidence of rifampicin elimination via CYP3A4. Auto-induction of rifampicin clearance was implemented via induction of AADAC, OATP1B1, and P-gp expression. Furthermore, induction of CYP3A4 has been incorporated, without impact on the PK of rifampicin itself. In addition to these induction processes, the DDI application of the presented model is extended to simultaneous dynamic competitive inhibition of CYP3A4 and P-gp. Several minimal or partial PBPK models of rifampicin13-16 and one full PBPK model17 have been published to date, but many of them do not account for auto-induction of rifampicin or lack the induction of P-gp. Induction of further CYP isoforms and transporters by rifampicin as well as inhibition of OATP is not yet accounted for, as this requires evaluation of appropriate victim drug models and of the DDI predictions with clinical data, which is beyond the scope of this study. However, the implementation of additional interaction parameters is technically a simple and straightforward extension of the current model.

The presented itraconazole model accounts for competitive inhibition of CYP3A4 by itraconazole itself and its three sequentially generated main metabolites. Adhering to the reported competitive mechanism of CYP3A4 inhibition by itraconazole and hydroxy-itraconazole,18 the strong observed nonlinearity and accumulation of itraconazole could not be adequately described using the inhibitory effects of parent drug and first metabolite, only. Therefore, the second and third metabolites were included, resulting in a model that slightly overpredicts the first dose of some studies, but accurately describes the steady-state plasma concentrations of intravenous and oral multiple-dose administration. The CYP3A4 inhibition constants of itraconazole and all three metabolites were fixed to literature values.18 Furthermore, the model correctly describes the strong food effects for both oral solution and capsule formulation, which is essential for modeling of the reported clinical studies.

The presented clarithromycin model is based on the PBPK model published by Moj et al.19 with small modifications. For DDI prediction, different compounds have to be coupled in one and the same individual with a specified expression of enzymes and transporters. Therefore, the clarithromycin model was adapted to the CYP3A4 expression profile reported by Nishimura et al.20 used in the other models (see Table S7 in Appendix S1). Furthermore, transport by OATP1B3 was removed, according to literature,21 and the values for pKa, lipophilicity, fraction unbound, and CYP3A4 Km were fixed to literature values. The adapted model precisely captures the plasma concentration-time profiles of all investigated studies with very low GMFEs (1.16 for AUC values and 1.11 for Cmax values; n = 15).

The presented midazolam model is a simple, very robust, and reliable model that has been successfully applied for DDI simulations with many different perpetrator models, as demonstrated in detail in Section 3 of Appendix S1. The presented alfentanil model has been established as a second CYP3A4 victim drug, to further evaluate the performance of the rifampicin model. It shows an accurate and precise performance in single compound simulations as well as in DDI predictions. Due to the lack of clinical studies with other perpetrator drugs it has only been coupled to the rifampicin model so far.

For the development of the presented digoxin model, a multitude of clinical studies (n = 38) was available in the literature, demonstrating the high interindividual variability in the PK of digoxin. A study measuring the P-gp protein abundance in human duodenal biopsies found considerable variation of more than eightfold in a group of 25 patients.22 Considering the large interindividual differences in the observed digoxin PK, the presented digoxin model shows a good descriptive and predictive performance. This was accomplished by incorporation of the drug target Na+/K+-ATPase as binding partner, and by increasing the relative P-gp expression in the intestinal mucosa, to accurately describe the plasma concentrations following intravenous as well as oral administration. This altered expression profile has been evaluated by prediction of the digoxin DDIs with rifampicin, itraconazole, and clarithromycin. Especially the prediction of the rifampicin-digoxin interaction was significantly improved applying the higher intestinal expression of P-gp.

PBPK modeling is a rapidly evolving field, including continuously improved software capabilities and steadily increasing knowledge in systems pharmacology. There are many different models for the drugs investigated in this study, built with many different software platforms, and comparing their features and performance would take a study of its own.

The presented DDI modeling network demonstrates a very good performance of the models for DDI prediction over the full range of reported DDI administration protocols. This is illustrated by concentration-time profiles, DDI AUC ratios, DDI Cmax ratios, and corresponding GMFEs. In addition, some of the presented models have been applied for DDI prediction with currently unpublished models, which are either confidential or pending publication, also yielding good results and further increasing the confidence in their predictive capacity. Now that a core of mutually evaluated models has been established, further models can be added to this DDI network and evaluated via simulation of published clinical DDI studies utilizing the models provided in this study.

In summary, whole-body PBPK models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin have been thoroughly built, and tested by DDI prediction within the presented network using different kinds of perpetrator (induction, competitive inhibition, and mechanism-based inactivation) and victim drugs (CYP3A4, P-gp), demonstrating that they reliably predict the observed data of all clinical DDI studies that have been reported for combinations of these drugs. The presented models are transparently documented and provided open-source as
supplementary material to this paper (Data S1-S6) and in the OSP repository (www.open-systems-pharmacology.org) for the drug development community to help understand and characterize the DDI potential of investigational drugs and to inform the design of clinical trials. This study lays a cornerstone for the qualification of the OSP platform with regard to reliable PBPK predictions of enzyme-mediated and transporter-mediated DDIs during model-informed drug development.

Supporting Information

Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website. (www.psp-journal.com)

Appendix S1. Model information and evaluation.

Data S1. Rifampin model file.
Data S2. Itraconazole model file.
Data S3. Clarithromycin model file.
Data S4. Midazolam model file.
Data S5. Alfentanil model file.
Data S6. Digoxin model file.

Funding. This study was sponsored by Bayer AG.

Conflict of Interest. S.F., T.E., and T.W. are employees of Bayer AG. T.L. has received research funding from Bayer AG. No potential conflicts of interest were disclosed by the other authors.

Author Contributions. N.H., S.F., T.E., and T.L. wrote the manuscript. N.H., S.F., T.E., and T.L. designed the research. N.H., S.F., D.M., H.B., T.W., and T.L. performed the research.

1. U.S. Food and Drug Administration. Clinical Drug Interaction Studies – Study Design, Data Analysis, and Clinical Implications. Draft Guidance for Industry. <https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf>., (October 2017).
2. European Medicines Agency. Guideline on the Investigation of Drug Interactions. CPM/PWP/560/95/Rev. 1 Corr. 2**<http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf>, (21 June 2012).
3. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1–17 (1999).
4. Fenner, K.S. et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173–181 (2009).
5. U.S. Food and Drug Administration. Drug development and drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin. Pharmacol. Ther. 89, 234–242 (2011).
6. Neuhoff, S. et al. Application of permeability-limited physiologically-based pharmacokinetic models: part II – prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J. Pharm. Sci. 102, 3161–3173 (2013).
7. Almond, L.M. et al. Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab. Dispos. 44, 821–832 (2016).
8. Guo, H. et al. A mechanistic physiologically based pharmacokinetic–enzyme turnover. Eur. J. Pharm. Sci. 43, 160–73 (2011).
9. Greenblatt, D.J. et al. Time course of recovery of cytochrome p450 3A4 after single doses of grapefruit juice. Clin. Pharmacol. Ther. 74, 121–129 (2003).
10. Reitman, M.L. et al. Rifampin’s acute inhibitory and chronic inductive drug interaction: experimental and model-based approaches to drug-drug interaction trial design. Clin. Pharmacol. Ther. 89, 234–242 (2011).
11. Neuhoff, S. et al. Application of permeability-limited physiologically-based pharmacokinetic models: part II – prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J. Pharm. Sci. 102, 3161–3173 (2013).
12. Assum, R. et al. Comprehensive PBPK model of rifampin for quantitative prediction of complex drug-drug interactions: CYP3A/2C9 induction and OATP inhibition effects. CPT Pharmacometrics Syst. Pharmacol. 7, 186–196 (2018).
13. Baneyx, G., Parrott, N., Meille, C., Illiads, A. & Lavé, T. Physiologically based pharmacokinetic modeling of CYP3A4A induction by rifampicin in human: influence of time between substrate and inducer administration. Eur. J. Pharm. Sci. 56, 1–15 (2014).
14. Iosiherranen, R., Kunze, K.L., Allen, K.E., Nelson, W.L. & Thummel, K.E. Role of CYP1A2 and CYP3A metabolism in CYP3A4 inhibition. Drug Metab. Dispos. 32, 1111–1131 (2013).
15. Isoherranen, R., Kunze, K.L., Allen, K.E., Nelson, W.L. & Thummel, K.E. Role of CYP1A2 and CYP3A metabolism in CYP3A4 inhibition. Drug Metab. Dispos. 32, 1111–1131 (2013).
16. Mo, D. et al. Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J. 19, 296–312 (2017).
17. Nishimura, Y., Yaguti, H., Yoshitshugu, H., Naito, S. & Satoh, T. Tissue distribution of mRNA expression of human cytochrome P450 450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. J. Pharm. Soc. Japan 123, 369–375 (2003).
18. Higgins, J.W., Ke, A.B. & Zamek-Gliszczynski, M.J. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab. Dispos. 42, 1780–1784 (2014).
19. Lown, K.S. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248–260 (1997).
20. Guest, E.J., Aarons, L., Houston, J.B., Rostami-Hodjegan, A. & Galetin, A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab. Dispos. 39, 170–173 (2011).
21. Kharasch, E.D. et al. The role of cytochrome P450 3A4 in allantoin clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87, 36–50 (1997).
22. Kharasch, E.D., Walker, A., Hoffer, C. & Sheffets, P. Intrahepatic and oral allantoin as in vivo probes for hepatic and first-pass cytochrome P450 3A4 activity: noninvasive assessment by use of pupillary miosis. Clin. Pharmacol. Ther. 76, 452–466 (2002).
23. Phimmasone, S. & Kharasch, E.D. A pilot evaluation of allantoin-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin. Pharmacol. Ther. 70, 505–517 (2001).
24. Link, S. et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br. J. Clin. Pharmacol. 66, 473–484 (2008).
25. Szalat, A. et al. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim. Biophys. Acts 1771, 839–844 (2007).
26. Gorski, J.C. et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin. Pharmacol. Ther. 74, 275–287 (2003).
27. Chung, E., Nafziger, A.N., Kuzierad, D.J. & Bertino, J.S. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79, 350–361 (2006).
28. Eap, C.B. et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur. J. Clin. Pharmacol. 60, 237–246 (2004).
29. Gurley, B. et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 46, 201–213 (2006).
30. Gurley, B.J. et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin. Pharmacol. Ther. 83, 61–69 (2008).
31. Backman, J.T., Kivistö, K.T., Oikkola, K.T. & Neuvonen, P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59, 7–13 (1996).
32. Backman, J.T., Kivistö, K.T., Oikkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during based pharmacokinetic modeling: impact of inactivation parameters and enzyme turnover. Eur. J. Pharm. Sci. 43, 160–73 (2011).
treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53–58 (1998).

36. Kharasch, E.D. et al. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin. Pharmacol. Ther. 90, 100–108 (2011).

37. Tucker, R.M. et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin. Infect. Dis. 14, 165–174 (1992).

38. Olkkola, K.T., Ahtonen, J. & Neuvonen, P.J. The effects of the systemic antymycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82, 511–516 (1996).

39. Templeton, I. et al. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin. Pharmacol. Ther. 88, 499–505 (2010).

40. Ahtonen, J., Olkkola, K.T. & Neuvonen, P.J. Effect of itraconazole and terbinafene on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br. J. Clin. Pharmacol. 40, 270–272 (1995).

41. Olkkola, K.T., Backman, J.T. & Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antymycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481–485 (1994).

42. Gorski, J.C. et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133–143 (1996).

43. Markert, C. et al. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur. J. Clin. Pharmacol. 69, 1785–1793 (2013).

44. Yeates, R.A., Laufen, H. & Zimmermann, T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int. J. Clin. Pharmacol. Ther. 34, 400–405 (1996).

45. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin. J. Clin. Invest. 104, 147–153 (1999).

46. Gurley, B.J., Swain, A., Williams, D.K., Barone, G. & Battu, S.K. Gauging the clinical significance of P-glycoprotein-mediated herb–drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. Food Res. 52, 772–779 (2008).

47. Larsen, U.L. et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand. J. Clin. Lab. Invest. 67, 123–134 (2007).

48. Jalava, K.M., Partanen, J. & Neuvonen, P.J. Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit. 19, 609–613 (1997).

49. Tsutsumi, K. et al. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1159–1164 (2002).

50. Rengelshausen, J. et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction. Br. J. Clin. Pharmacol. 56, 32–38 (2003).